Login Register Cart 0
Generic placeholder image

当代肿瘤药物靶点

Editor-in-Chief

ISSN (Print): 1568-0096
ISSN (Online): 1873-5576

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe Translate in English
Review Article

肝细胞癌相关酪氨酸激酶抑制剂耐药的分子机制

卷 22, 期 6, 2022

发表于: 10 May, 2022

页: [454 - 462] 页: 9

弟呕挨: 10.2174/1568009622666220330151725

价格: $65

摘要

肝细胞癌（HCC）是癌症相关死亡的第二大原因，其具有高发病率和较晚的早期诊断。酪氨酸激酶抑制剂（Tyrosine kinase inhibitors, TKIs）是一类小分子靶向药物，其临床疗效显著，临床不良反应发生率低，因此主要用于化疗后HCC的临床治疗。然而，耐药性对索拉非尼和其他可用于治疗晚期HCC的TKIs提出了一个重大挑战。最近的机制研究表明，上皮-间充质转化（EMT）、ATP结合盒（ABC）转运体、缺氧、自噬和血管生成参与了HCC患者的凋亡、血管生成、HCC细胞增殖和TKI耐药。探索和克服这种耐药机制对于提高TKI耐药的HCC患者的治疗效果至关重要。。本文旨在总结近年来提出的可能的耐药机制，以及在HCC背景下逆转TKI耐药的方法。

关键词: 肝细胞癌，酪氨酸激酶抑制剂，耐药机制，索拉非尼，靶蛋白，分子机制。

« Previous Next »
图形摘要

[1]
Tang, W.; Chen, Z.; Zhang, W.; Cheng, Y.; Zhang, B.; Wu, F.; Wang, Q.; Wang, S.; Rong, D.; Reiter, F.P.; De Toni, E.N.; Wang, X. The mechanisms of sorafenib resistance in hepatocellular carcinoma: Theoretical basis and therapeutic aspects. Signal Transduct. Target. Ther., 2020, 5(1), 87.
[http://dx.doi.org/10.1038/s41392-020-0187-x] [PMID: 32532960]
[2]
Huang, A.; Yang, X.R.; Chung, W.Y.; Dennison, A.R.; Zhou, J. Targeted therapy for hepatocellular carcinoma. Signal Transduct. Target. Ther., 2020, 5(1), 146.
[http://dx.doi.org/10.1038/s41392-020-00264-x] [PMID: 32782275]
[3]
Younossi, Z.M. The efficacy of new antiviral regimens for hepatitis C infection: Evidence from a systematic review. Hepatology, 2018, 67(3), 1160-1162.
[http://dx.doi.org/10.1002/hep.29580] [PMID: 29023922]
[4]
Abou-Alfa, G.K.; Meyer, T.; Cheng, A.L.; El-Khoueiry, A.B.; Rimassa, L.; Ryoo, B.Y.; Cicin, I.; Merle, P.; Chen, Y.; Park, J.W.; Blanc, J.F.; Bolondi, L.; Klümpen, H.J.; Chan, S.L.; Zagonel, V.; Pressiani, T.; Ryu, M.H.; Venook, A.P.; Hessel, C.; Borgman-Hagey, A.E.; Schwab, G.; Kelley, R.K. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N. Engl. J. Med., 2018, 379(1), 54-63.
[http://dx.doi.org/10.1056/NEJMoa1717002] [PMID: 29972759]
[5]
Finn, R.S.; Zhu, A.X.; Farah, W.; Almasri, J.; Zaiem, F.; Prokop, L.J.; Murad, M.H.; Mohammed, K. Therapies for advanced stage hepatocellular carcinoma with macrovascular invasion or metastatic disease: A systematic review and meta-analysis. Hepatology, 2018, 67(1), 422-435.
[http://dx.doi.org/10.1002/hep.29486] [PMID: 28881497]
[6]
Ogasawara, S.; Chiba, T.; Ooka, Y.; Suzuki, E.; Kanogawa, N.; Saito, T.; Motoyama, T.; Tawada, A.; Kanai, F.; Yokosuka, O. Post-progression survival in patients with advanced hepatocellular carcinoma resistant to sorafenib. Invest. New Drugs, 2016, 34(2), 255-260.
[http://dx.doi.org/10.1007/s10637-016-0323-1] [PMID: 26769245]
[7]
Sui, Z.G.; Xue, H.W.; Jin, F.B.; Leng, P. Sorafenib plus capecitabine for patients with advanced hepatocellular carcinoma. Zhongguo Yaoke Daxue Xuebao, 2008, 19, 848-849.
[8]
Matsusaka, S.; Hanna, D.L.; Ning, Y.; Yang, D.; Cao, S.; Berger, M.D.; Miyamoto, Y.; Suenaga, M.; Dan, S.; Mashima, T.; Seimiya, H.; Zhang, W.; Lenz, H.J. Epidermal growth factor receptor mRNA expression: A potential molecular escape mechanism from regorafenib. Cancer Sci., 2020, 111(2), 441-450.
[http://dx.doi.org/10.1111/cas.14273] [PMID: 31821662]
[9]
Han, Z.; He, Z.; Wang, C.; Wang, Q. The effect of apatinib in the treatment of sorafenib resistant metastatic hepatocellular carcinoma: A case report. Medicine (Baltimore), 2018, 97(49), e13388.
[http://dx.doi.org/10.1097/MD.0000000000013388] [PMID: 30544412]
[10]
Galle, E.; Thienpont, B.; Cappuyns, S.; Venken, T.; Busschaert, P.; Van Haele, M.; Van Cutsem, E.; Roskams, T.; van Pelt, J.; Verslype, C.; Dekervel, J.; Lambrechts, D. DNA methylation-driven EMT is a common mechanism of resistance to various therapeutic agents in cancer. Clin. Epigenetics, 2020, 12(1), 27.
[http://dx.doi.org/10.1186/s13148-020-0821-z] [PMID: 32059745]
[11]
Juengpanich, S.; Topatana, W.; Lu, C.; Staiculescu, D.; Li, S.; Cao, J.; Lin, J.; Hu, J.; Chen, M.; Chen, J.; Cai, X. Role of cellular, molecular and tumor microenvironment in hepatocellular carcinoma: Possible targets and future directions in the regorafenib era. Int. J. Cancer, 2020, 147(7), 1778-1792.
[http://dx.doi.org/10.1002/ijc.32970] [PMID: 32162677]
[12]
Deng, J.; Shao, J.; Markowitz, J.S.; An, G. ABC transporters in multi-drug resistance and ADME-Tox of small molecule tyrosine kinase inhibitors. Pharm. Res., 2014, 31(9), 2237-2255.
[http://dx.doi.org/10.1007/s11095-014-1389-0] [PMID: 24842659]
[13]
Atwa, S.M.; Odenthal, M.; El Tayebi, H.M. Genetic heterogeneity, therapeutic hurdle confronting sorafenib and immune checkpoint inhibitors in hepatocellular carcinoma. Cancers (Basel), 2021, 13(17), 4343.
[14]
Kuczynski, E.A.; Lee, C.R.; Man, S.; Chen, E.; Kerbel, R.S. Effects of sorafenib dose on acquired reversible resistance and toxicity in hepatocellular carcinoma. Cancer Res., 2015, 75(12), 2510-2519.
[http://dx.doi.org/10.1158/0008-5472.CAN-14-3687] [PMID: 25908587]
[15]
Liu, X.; Qin, S. Immune checkpoint inhibitors in hepatocellular carcinoma: Opportunities and challenges. Oncologist, 2019, 24(S1)(Suppl. 1), S3-S10.
[http://dx.doi.org/10.1634/theoncologist.2019-IO-S1-s01] [PMID: 30819826]
[16]
Liu, Z.; Lin, Y.; Zhang, J.; Zhang, Y.; Li, Y.; Liu, Z.; Li, Q.; Luo, M.; Liang, R.; Ye, J. Molecular targeted and immune checkpoint therapy for advanced hepatocellular carcinoma. J. Exp. Clin. Cancer Res., 2019, 38(1), 447.
[http://dx.doi.org/10.1186/s13046-019-1412-8] [PMID: 31684985]
[17]
Toledo, R.A.; Garralda, E.; Mitsi, M.; Pons, T.; Monsech, J.; Vega, E.; Otero, Á.; Albarran, M.I.; Baños, N.; Durán, Y.; Bonilla, V.; Sarno, F.; Camacho-Artacho, M.; Sanchez-Perez, T.; Perea, S.; Álvarez, R.; De Martino, A.; Lietha, D.; Blanco-Aparicio, C.; Cubillo, A.; Domínguez, O.; Martínez-Torrecuadrada, J.L.; Hidalgo, M. Exome sequencing of plasma DNA portrays the mutation landscape of colorectal cancer and discovers mutated VEGFR2 receptors as modulators of antiangiogenic therapies. Clin. Cancer Res., 2018, 24(15), 3550-3559.
[http://dx.doi.org/10.1158/1078-0432.CCR-18-0103] [PMID: 29588308]
[18]
Sueangoen, N.; Tantiwetrueangdet, A.; Panvichian, R. HCC-derived EGFR mutants are functioning, EGF-dependent, and erlotinib-resistant. Cell Biosci., 2020, 10(1), 41.
[http://dx.doi.org/10.1186/s13578-020-00407-1] [PMID: 32190291]
[19]
Grillo, E.; Corsini, M.; Ravelli, C.; di Somma, M.; Zammataro, L.; Monti, E.; Presta, M.; Mitola, S. A novel variant of VEGFR2 identified by a pan-cancer screening of recurrent somatic mutations in the catalytic domain of tyrosine kinase receptors enhances tumor growth and metastasis. Cancer Lett., 2021, 496, 84-92.
[http://dx.doi.org/10.1016/j.canlet.2020.09.027] [PMID: 33035615]
[20]
Gorre, M.E.; Mohammed, M.; Ellwood, K.; Hsu, N.; Paquette, R.; Rao, P.N.; Sawyers, C.L. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science, 2001, 293(5531), 876-880.
[http://dx.doi.org/10.1126/science.1062538] [PMID: 11423618]
[21]
Minnelli, C.; Laudadio, E.; Mobbili, G.; Galeazzi, R. Conformational insight on WT- and mutated-EGFR receptor activation and inhibition by epigallocatechin-3-gallate: Over a rational basis for the design of selective non-small-cell lung anticancer agents. Int. J. Mol. Sci., 2020, 21(5), E1721.
[http://dx.doi.org/10.3390/ijms21051721] [PMID: 32138321]
[22]
Negri, F.V.; Dal Bello, B.; Porta, C.; Campanini, N.; Rossi, S.; Tinelli, C.; Poggi, G.; Missale, G.; Fanello, S.; Salvagni, S.; Ardizzoni, A.; Maria, S.E. Expression of pERK and VEGFR-2 in advanced hepatocellular carcinoma and resistance to sorafenib treatment. Liver Int., 2015, 35(8), 2001-2008.
[http://dx.doi.org/10.1111/liv.12778] [PMID: 25559745]
[23]
Ji, L.; Lin, Z.; Wan, Z.; Xia, S.; Jiang, S.; Cen, D.; Cai, L.; Xu, J.; Cai, X. miR-486-3p mediates hepatocellular carcinoma sorafenib resistance by targeting FGFR4 and EGFR. Cell Death Dis., 2020, 11(4), 250.
[http://dx.doi.org/10.1038/s41419-020-2413-4] [PMID: 32313144]
[24]
Gusenbauer, S.; Vlaicu, P.; Ullrich, A. HGF induces novel EGFR functions involved in resistance formation to tyrosine kinase inhibitors. Oncogene, 2013, 32(33), 3846-3856.
[http://dx.doi.org/10.1038/onc.2012.396] [PMID: 23045285]
[25]
Ezzoukhry, Z.; Louandre, C.; Trécherel, E.; Godin, C.; Chauffert, B.; Dupont, S.; Diouf, M.; Barbare, J.C.; Mazière, J.C.; Galmiche, A. EGFR activation is a potential determinant of primary resistance of hepatocellular carcinoma cells to sorafenib. Int. J. Cancer, 2012, 131(12), 2961-2969.
[http://dx.doi.org/10.1002/ijc.27604] [PMID: 22514082]
[26]
Scartozzi, M.; Faloppi, L.; Svegliati Baroni, G.; Loretelli, C.; Piscaglia, F.; Iavarone, M.; Toniutto, P.; Fava, G.; De Minicis, S.; Mandolesi, A.; Bianconi, M.; Giampieri, R.; Granito, A.; Facchetti, F.; Bitetto, D.; Marinelli, S.; Venerandi, L.; Vavassori, S.; Gemini, S.; D’Errico, A.; Colombo, M.; Bolondi, L.; Bearzi, I.; Benedetti, A.; Cascinu, S. VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: The ALICE-1 study. Int. J. Cancer, 2014, 135(5), 1247-1256.
[http://dx.doi.org/10.1002/ijc.28772] [PMID: 24510746]
[27]
Gurzu, S.; Kobori, L.; Fodor, D.; Jung, I. Epithelial mesenchymal and endothelial mesenchymal transitions in hepatocellular carcinoma: A review. BioMed Res. Int., 2019, 2019, 2962580.
[http://dx.doi.org/10.1155/2019/2962580] [PMID: 31781608]
[28]
Cabral, L.K.D.; Tiribelli, C.; Sukowati, C.H.C. Sorafenib resistance in hepatocellular carcinoma: The relevance of genetic heterogeneity. Cancers (Basel), 2020, 12(6), E1576.
[http://dx.doi.org/10.3390/cancers12061576] [PMID: 32549224]
[29]
Zhang, P.F.; Wang, F.; Wu, J.; Wu, Y.; Huang, W.; Liu, D.; Huang, X.Y.; Zhang, X.M.; Ke, A.W. LncRNA SNHG3 induces EMT and sorafenib resistance by modulating the miR-128/CD151 pathway in hepatocellular carcinoma. J. Cell. Physiol., 2019, 234(3), 2788-2794.
[http://dx.doi.org/10.1002/jcp.27095] [PMID: 30132868]
[30]
Xu, Y.; Xu, H.; Li, M.; Wu, H.; Guo, Y.; Chen, J.; Shan, J.; Chen, X.; Shen, J.; Ma, Q.; Liu, J.; Wang, M.; Zhao, W.; Hong, J.; Qi, Y.; Yao, C.; Zhang, Q.; Yang, Z.; Qian, C.; Li, J. KIAA1199 promotes sorafenib tolerance and the metastasis of hepatocellular carcinoma by activating the EGF/EGFR-dependent epithelial-mesenchymal transition program. Cancer Lett., 2019, 454, 78-89.
[http://dx.doi.org/10.1016/j.canlet.2019.03.049] [PMID: 30980868]
[31]
Hu, B.; Cheng, J.W.; Hu, J.W.; Li, H.; Ma, X.L.; Tang, W.G.; Sun, Y.F.; Guo, W.; Huang, A.; Zhou, K.Q.; Gao, P.T.; Cao, Y.; Qiu, S.J.; Zhou, J.; Fan, J.; Yang, X.R. KPNA3 confers sorafenib resistance to advanced hepatocellular carcinoma via TWIST regulated epithelial-mesenchymal transition. J. Cancer, 2019, 10(17), 3914-3925.
[http://dx.doi.org/10.7150/jca.31448] [PMID: 31417635]
[32]
Wang, J.; Zhang, N.; Han, Q.; Lu, W.; Wang, L.; Yang, D.; Zheng, M.; Zhang, Z.; Liu, H.; Lee, T.H.; Zhou, X.Z.; Lu, K.P. Pin1 inhibition reverses the acquired resistance of human hepatocellular carcinoma cells to Regorafenib via the Gli1/Snail/E-cadherin pathway. Cancer Lett., 2019, 444, 82-93.
[http://dx.doi.org/10.1016/j.canlet.2018.12.010] [PMID: 30583078]
[33]
Dekervel, J.; Bulle, A.; Windmolders, P.; Lambrechts, D.; Van Cutsem, E.; Verslype, C.; van Pelt, J. Acriflavine inhibits acquired drug resistance by blocking the epithelial-to-mesenchymal transition and the unfolded protein response. Transl. Oncol., 2017, 10(1), 59-69.
[http://dx.doi.org/10.1016/j.tranon.2016.11.008] [PMID: 27987431]
[34]
Tao, L.; Shu-Ling, W.; Jing-Bo, H.; Ying, Z.; Rong, H.; Xiang-Qun, L.; Wen-Jie, C.; Lin-Fu, Z. MiR-451a attenuates doxorubicin resistance in lung cancer via suppressing Epithelial Mesenchymal Transition (EMT) through targeting c-Myc. Biomed. Pharmacother., 2020, 125, 109962.
[http://dx.doi.org/10.1016/j.biopha.2020.109962] [PMID: 32106373]
[35]
Chen, W.; Yang, J.; Zhang, Y.; Cai, H.; Chen, X.; Sun, D. Regorafenib reverses HGF-induced sorafenib resistance by inhibiting epithelial-mesenchymal transition in hepatocellular carcinoma. FEBS Open Bio, 2019, 9(2), 335-347.
[http://dx.doi.org/10.1002/2211-5463.12578] [PMID: 30761258]
[36]
Mohammad, I.S.; He, W.; Yin, L. Understanding of human ATP binding cassette superfamily and novel multidrug resistance modulators to overcome MDR. Biomed. Pharmacother., 2018, 100, 335-348.
[http://dx.doi.org/10.1016/j.biopha.2018.02.038] [PMID: 29453043]
[37]
Zhang, H.; Xu, H.; Ashby, C.R.; Assaraf, Y.G.; Chen, Z.S.; Liu, H.M. Chemical molecular-based approach to overcome multidrug resistance in cancer by targeting P-glycoprotein (P-gp). Med. Res. Rev., 2020.
[PMID: 33047304]
[38]
Li, W.; Zhang, H.; Assaraf, Y.G.; Zhao, K.; Xu, X.; Xie, J.; Yang, D-H.; Chen, Z-S. Overcoming ABC transporter-mediated multidrug resistance: Molecular mechanisms and novel therapeutic drug strategies. Drug Resist. Updat., 2016, 27, 14-29.
[http://dx.doi.org/10.1016/j.drup.2016.05.001] [PMID: 27449595]
[39]
Bae, S.; D’Cunha, R.; Shao, J.; An, G. Effect of 5,7-dimethoxyflavone on Bcrp1-mediated transport of sorafenib in vitro and in vivo in mice. Eur. J. Pharm. Sci., 2018, 117, 27-34.
[http://dx.doi.org/10.1016/j.ejps.2018.02.004] [PMID: 29425861]
[40]
Beretta, G.L.; Cassinelli, G.; Pennati, M.; Zuco, V.; Gatti, L. Overcoming ABC transporter-mediated multidrug resistance: The dual role of tyrosine kinase inhibitors as multitargeting agents. Eur. J. Med. Chem., 2017, 142, 271-289.
[http://dx.doi.org/10.1016/j.ejmech.2017.07.062] [PMID: 28851502]
[41]
Di Giacomo, S.; Briz, O.; Monte, M.J.; Sanchez-Vicente, L.; Abete, L.; Lozano, E.; Mazzanti, G.; Di Sotto, A.; Marin, J.J.G. Chemosensitization of hepatocellular carcinoma cells to sorafenib by β-caryophyllene oxide-induced inhibition of ABC export pumps. Arch. Toxicol., 2019, 93(3), 623-634.
[http://dx.doi.org/10.1007/s00204-019-02395-9] [PMID: 30659321]
[42]
Huang, Y.S.; Xue, Z.; Zhang, H. Sorafenib reverses resistance of gastric cancer to treatment by cisplatin through down-regulating MDR1 expression. Med. Oncol., 2015, 32(2), 470.
[http://dx.doi.org/10.1007/s12032-014-0470-1] [PMID: 25579168]
[43]
Mazard, T.; Causse, A.; Simony, J.; Leconet, W.; Vezzio-Vie, N.; Torro, A.; Jarlier, M.; Evrard, A.; Del Rio, M.; Assenat, E.; Martineau, P.; Ychou, M.; Robert, B.; Gongora, C. Sorafenib overcomes irinotecan resistance in colorectal cancer by inhibiting the ABCG2 drug-efflux pump. Mol. Cancer Ther., 2013, 12(10), 2121-2134.
[http://dx.doi.org/10.1158/1535-7163.MCT-12-0966] [PMID: 23960095]
[44]
Wang, Y.J.; Zhang, Y.K.; Zhang, G.N.; Al Rihani, S.B.; Wei, M.N.; Gupta, P.; Zhang, X.Y.; Shukla, S.; Ambudkar, S.V.; Kaddoumi, A.; Shi, Z.; Chen, Z.S. Regorafenib overcomes chemotherapeutic multidrug resistance mediated by ABCB1 transporter in colorectal cancer: In vitro and in vivo study. Cancer Lett., 2017, 396, 145-154.
[http://dx.doi.org/10.1016/j.canlet.2017.03.011] [PMID: 28302530]
[45]
Méndez-Blanco, C.; Fondevila, F.; García-Palomo, A.; González-Gallego, J.; Mauriz, J.L. Sorafenib resistance in hepatocarcinoma: Role of hypoxia-inducible factors. Exp. Mol. Med., 2018, 50(10), 1-9.
[http://dx.doi.org/10.1038/s12276-018-0159-1] [PMID: 30315182]
[46]
Zhao, C.X.; Luo, C.L.; Wu, X.H. Hypoxia promotes 786-O cells invasiveness and resistance to sorafenib via HIF-2α/COX-2. Med. Oncol., 2015, 32(1), 419.
[http://dx.doi.org/10.1007/s12032-014-0419-4] [PMID: 25487445]
[47]
Lu, Y.; Liu, Y.; Oeck, S.; Glazer, P.M. Hypoxia promotes resistance to EGFR inhibition in NSCLC cells via the histone demethylases, LSD1 and PLU-1. Mol. Cancer Res., 2018, 16(10), 1458-1469.
[http://dx.doi.org/10.1158/1541-7786.MCR-17-0637] [PMID: 29934325]
[48]
Malale, K.; Fu, J.; Qiu, L.; Zhan, K.; Gan, X.; Mei, Z. Hypoxia-induced aquaporin-3 changes hepatocellular carcinoma cell sensitivity to sorafenib by activating the PI3K/Akt signaling pathway. Cancer Manag. Res., 2020, 12, 4321-4333.
[http://dx.doi.org/10.2147/CMAR.S243918] [PMID: 32606928]
[49]
Méndez-Blanco, C.; Fondevila, F.; Fernández-Palanca, P.; García-Palomo, A.; Pelt, J.V.; Verslype, C.; González-Gallego, J.; Mauriz, J.L. Stabilization of hypoxia-inducible factors and BNIP3 promoter methylation contribute to acquired sorafenib resistance in human hepatocarcinoma cells. Cancers (Basel), 2019, 11(12), E1984.
[http://dx.doi.org/10.3390/cancers11121984] [PMID: 31835431]
[50]
Dong, X.F.; Liu, T.Q.; Zhi, X.T.; Zou, J.; Zhong, J.T.; Li, T.; Mo, X.L.; Zhou, W.; Guo, W.W.; Liu, X.; Chen, Y.Y.; Li, M.Y.; Zhong, X.G.; Han, Y.M.; Wang, Z.H.; Dong, Z.R. COX-2/PGE2 axis regulates HIF2α activity to promote hepatocellular carcinoma hypoxic response and reduce the sensitivity of sorafenib treatment. Clin. Cancer Res., 2018, 24(13), 3204-3216.
[http://dx.doi.org/10.1158/1078-0432.CCR-17-2725] [PMID: 29514844]
[51]
Liang, Y.; Zheng, T.; Song, R.; Wang, J.; Yin, D.; Wang, L.; Liu, H.; Tian, L.; Fang, X.; Meng, X.; Jiang, H.; Liu, J.; Liu, L. Hypoxia-mediated sorafenib resistance can be overcome by EF24 through Von Hippel-Lindau tumor suppressor-dependent HIF-α inhibition in hepatocellular carcinoma. Hepatology, 2013, 57(5), 1847-1857.
[http://dx.doi.org/10.1002/hep.26224] [PMID: 23299930]
[52]
Qiu, Y.; Shan, W.; Yang, Y.; Jin, M.; Dai, Y.; Yang, H.; Jiao, R.; Xia, Y.; Liu, Q.; Ju, L.; Huang, G.; Zhang, J.; Yang, L.; Li, L.; Li, Y. Reversal of sorafenib resistance in hepatocellular carcinoma: Epigenetically regulated disruption of 14-3-3η/hypoxia-inducible factor-1α. Cell Death Discov., 2019, 5(1), 120.
[http://dx.doi.org/10.1038/s41420-019-0200-8] [PMID: 31341646]
[53]
Collet, G.; Lamerant-Fayel, N.; Tertil, M.; El Hafny-Rahbi, B.; Stepniewski, J.; Guichard, A.; Foucault-Collet, A.; Klimkiewicz, K.; Petoud, S.; Matejuk, A.; Grillon, C.; Jozkowicz, A.; Dulak, J.; Kieda, C. Hypoxia-regulated overexpression of soluble VEGFR2 controls angiogenesis and inhibits tumor growth. Mol. Cancer Ther., 2014, 13(1), 165-178.
[http://dx.doi.org/10.1158/1535-7163.MCT-13-0637] [PMID: 24170768]
[54]
Nobre, A.R.; Entenberg, D.; Wang, Y.; Condeelis, J.; Aguirre-Ghiso, J.A. The different routes to metastasis via hypoxia-regulated programs. Trends Cell Biol., 2018, 28(11), 941-956.
[http://dx.doi.org/10.1016/j.tcb.2018.06.008] [PMID: 30041830]
[55]
Ahmadi, M.; Ahmadihosseini, Z.; Allison, S.J.; Begum, S.; Rockley, K.; Sadiq, M.; Chintamaneni, S.; Lokwani, R.; Hughes, N.; Phillips, R.M. Hypoxia modulates the activity of a series of clinically approved tyrosine kinase inhibitors. Br. J. Pharmacol., 2014, 171(1), 224-236.
[http://dx.doi.org/10.1111/bph.12438] [PMID: 24117380]
[56]
Han, R.; Li, S. Regorafenib delays the proliferation of hepatocellular carcinoma by inducing autophagy. Pharmazie, 2018, 73(4), 218-222.
[PMID: 29609689]
[57]
Sun, T.; Liu, H.; Ming, L. Multiple roles of autophagy in the sorafenib resistance of hepatocellular carcinoma. Cell. Physiol. Biochem., 2017, 44(2), 716-727.
[http://dx.doi.org/10.1159/000485285] [PMID: 29169150]
[58]
Tong, M.; Che, N.; Zhou, L.; Luk, S.T.; Kau, P.W.; Chai, S.; Ngan, E.S.; Lo, C.M.; Man, K.; Ding, J.; Lee, T.K.; Ma, S. Efficacy of annexin A3 blockade in sensitizing hepatocellular carcinoma to sorafenib and regorafenib. J. Hepatol., 2018, 69(4), 826-839.
[http://dx.doi.org/10.1016/j.jhep.2018.05.034] [PMID: 29885413]
[59]
Wu, F.Q.; Fang, T.; Yu, L.X.; Lv, G.S.; Lv, H.W.; Liang, D.; Li, T.; Wang, C.Z.; Tan, Y.X.; Ding, J.; Chen, Y.; Tang, L.; Guo, L.N.; Tang, S.H.; Yang, W.; Wang, H.Y. ADRB2 signaling promotes HCC progression and sorafenib resistance by inhibiting autophagic degradation of HIF1α. J. Hepatol., 2016, 65(2), 314-324.
[http://dx.doi.org/10.1016/j.jhep.2016.04.019] [PMID: 27154061]
[60]
Lu, S.; Yao, Y.; Xu, G.; Zhou, C.; Zhang, Y.; Sun, J.; Jiang, R.; Shao, Q.; Chen, Y. CD24 regulates sorafenib resistance via activating autophagy in hepatocellular carcinoma. Cell Death Dis., 2018, 9(6), 646.
[http://dx.doi.org/10.1038/s41419-018-0681-z] [PMID: 29844385]
[61]
Li, X.; Zhou, Y.; Yang, L.; Ma, Y.; Peng, X.; Yang, S.; Li, H.; Liu, J. LncRNA NEAT1 promotes autophagy via regulating miR-204/ATG3 and enhanced cell resistance to sorafenib in hepatocellular carcinoma. J. Cell. Physiol., 2020, 235(4), 3402-3413.
[http://dx.doi.org/10.1002/jcp.29230] [PMID: 31549407]
[62]
Jing, Z.; Ye, X.; Ma, X.; Hu, X.; Yang, W.; Shi, J.; Chen, G.; Gong, L. SNGH16 regulates cell autophagy to promote sorafenib resistance through suppressing miR-23b-3p via sponging EGR1 in hepatocellular carcinoma. Cancer Med., 2020, 9(12), 4324-4338.
[http://dx.doi.org/10.1002/cam4.3020] [PMID: 32324343]
[63]
Zhai, B.; Hu, F.; Jiang, X.; Xu, J.; Zhao, D.; Liu, B.; Pan, S.; Dong, X.; Tan, G.; Wei, Z.; Qiao, H.; Jiang, H.; Sun, X. Inhibition of Akt reverses the acquired resistance to sorafenib by switching protective autophagy to autophagic cell death in hepatocellular carcinoma. Mol. Cancer Ther., 2014, 13(6), 1589-1598.
[http://dx.doi.org/10.1158/1535-7163.MCT-13-1043] [PMID: 24705351]
[64]
Nassour, J.; Radford, R.; Correia, A.; Fusté, J.M.; Schoell, B.; Jauch, A.; Shaw, R.J.; Karlseder, J. Autophagic cell death restricts chromosomal instability during replicative crisis. Nature, 2019, 565(7741), 659-663.
[http://dx.doi.org/10.1038/s41586-019-0885-0] [PMID: 30675059]
[65]
Xiong, Y.Q.; Sun, H.C.; Zhang, W.; Zhu, X.D.; Zhuang, P.Y.; Zhang, J.B.; Wang, L.; Wu, W.Z.; Qin, L.X.; Tang, Z.Y. Human hepatocellular carcinoma tumor-derived endothelial cells manifest increased angiogenesis capability and drug resistance compared with normal endothelial cells. Clin. Cancer Res., 2009, 15(15), 4838-4846.
[http://dx.doi.org/10.1158/1078-0432.CCR-08-2780] [PMID: 19638466]
[66]
Li, D.; Wang, T.; Sun, F.F.; Feng, J.Q.; Peng, J.J.; Li, H.; Wang, C.; Wang, D.; Liu, Y.; Bai, Y.D.; Shi, M.L.; Zhang, T. MicroRNA-375 represses tumor angiogenesis and reverses resistance to sorafenib in hepatocarcinoma. Cancer Gene Ther., 2020.
[PMID: 32616906]
[67]
Yang, W.; Li, Z.; Qin, R.; Wang, X.; An, H.; Wang, Y.; Zhu, Y.; Liu, Y.; Cai, S.; Chen, S.; Sun, T.; Meng, J.; Yang, C. YY1 promotes endothelial cell-dependent tumor angiogenesis in hepatocellular carcinoma by transcriptionally activating VEGFA. Front. Oncol., 2019, 9, 1187.
[http://dx.doi.org/10.3389/fonc.2019.01187] [PMID: 31799179]
[68]
Kuczynski, E.A.; Yin, M.; Bar-Zion, A.; Lee, C.R.; Butz, H.; Man, S.; Daley, F.; Vermeulen, P.B.; Yousef, G.M.; Foster, F.S.; Reynolds, A.R.; Kerbel, R.S. Co-option of liver vessels and not sprouting angiogenesis drives acquired sorafenib resistance in hepatocellular carcinoma. J. Natl. Cancer Inst., 2016, 108(8), djw030.
[http://dx.doi.org/10.1093/jnci/djw030] [PMID: 27059374]
[69]
Liao, Z.H.; Zhu, H.Q.; Chen, Y.Y.; Chen, R.L.; Fu, L.X.; Li, L.; Zhou, H.; Zhou, J.L.; Liang, G. The epigallocatechin gallate derivative Y6 inhibits human hepatocellular carcinoma by inhibiting angiogenesis in MAPK/ERK1/2 and PI3K/AKT/HIF-α/VEGF dependent pathways. J. Ethnopharmacol., 2020, 259, 112852.
[http://dx.doi.org/10.1016/j.jep.2020.112852] [PMID: 32278759]
[70]
Zanjani, L.S.; Madjd, Z.; Rasti, A.; Asgari, M.; Abolhasani, M.; Tam, K.J.; Roudi, R.; Mælandsmo, G.M.; Fodstad, Ø.; Andersson, Y. Spheroid-derived cells from renal adenocarcinoma have low telomerase activity and high stem-like and invasive characteristics. Front. Oncol., 2019, 9, 1302.
[71]
Liu, R.; Li, Y.; Tian, L.; Shi, H.; Wang, J.; Liang, Y.; Sun, B.; Wang, S.; Zhou, M.; Wu, L.; Nie, J.; Lin, B.; Tang, S.; Zhang, Y.; Wang, G.; Zhang, C.; Han, J.; Xu, B.; Liu, L.; Gong, K.; Zheng, T. Gankyrin drives metabolic reprogramming to promote tumorigenesis, metastasis and drug resistance through activating β-catenin/c-Myc signaling in human hepatocellular carcinoma. Cancer Lett., 2019, 443, 34-46.
[http://dx.doi.org/10.1016/j.canlet.2018.11.030] [PMID: 30503555]
[72]
Saraswati, S.; Alhaider, A.; Abdelgadir, A.M.; Tanwer, P.; Korashy, H.M. Phloretin attenuates STAT-3 activity and overcomes sorafenib resistance targeting SHP-1-mediated inhibition of STAT3 and Akt/VEGFR2 pathway in hepatocellular carcinoma. Cell Commun. Signal., 2019, 17(1), 127.
[http://dx.doi.org/10.1186/s12964-019-0430-7] [PMID: 31619257]
[73]
Zeidan, M.A.; Mostafa, A.S.; Gomaa, R.M.; Abou-Zeid, L.A.; El-Mesery, M.; El-Sayed, M.A.; Selim, K.B. Design, synthesis and docking study of novel picolinamide derivatives as anticancer agents and VEGFR-2 inhibitors. Eur. J. Med. Chem., 2019, 168, 315-329.
[http://dx.doi.org/10.1016/j.ejmech.2019.02.050] [PMID: 30826508]
[74]
Lin, C.H.; Elkholy, K.H.; Wani, N.A.; Li, D.; Hu, P.; Barajas, J.M.; Yu, L.; Zhang, X.; Jacob, S.T.; Khan, W.N.; Bai, X.F.; Noonan, A.M.; Ghoshal, K. Ibrutinib potentiates antihepatocarcinogenic efficacy of sorafenib by targeting EGFR in tumor cells and BTK in immune cells in the stroma. Mol. Cancer Ther., 2020, 19(2), 384-396.
[http://dx.doi.org/10.1158/1535-7163.MCT-19-0135] [PMID: 31582534]
[75]
Chuma, M.; Uojima, H.; Numata, K.; Hidaka, H.; Toyoda, H.; Hiraoka, A.; Tada, T.; Hirose, S.; Atsukawa, M.; Itokawa, N.; Arai, T.; Kako, M.; Nakazawa, T.; Wada, N.; Iwasaki, S.; Miura, Y.; Hishiki, S.; Nishigori, S.; Morimoto, M.; Hattori, N.; Ogushi, K.; Nozaki, A.; Fukuda, H.; Kagawa, T.; Michitaka, K.; Kumada, T.; Maeda, S. Early changes in circulating FGF19 and Ang-2 levels as possible predictive biomarkers of clinical response to lenvatinib therapy in hepatocellular carcinoma. Cancers (Basel), 2020, 12(2), E293.
[http://dx.doi.org/10.3390/cancers12020293] [PMID: 31991869]
[76]
Liu, J.; Qiu, W.C.; Shen, X.Y.; Sun, G.C. Bioinformatics analysis revealed hub genes and pathways involved in sorafenib resistance in hepatocellular carcinoma. Math. Biosci. Eng., 2019, 16(6), 6319-6334.
[http://dx.doi.org/10.3934/mbe.2019315] [PMID: 31698564]
[77]
Guo, Q.R.; Zhang, L.L.; Liu, J.F.; Li, Z.; Li, J.J.; Zhou, W.M.; Wang, H.; Li, J.Q.; Liu, D.Y.; Yu, X.Y.; Zhang, J.Y. Multifunctional microfluidic chip for cancer diagnosis and treatment. Nanotheranostics, 2021, 5(1), 73-89.
[http://dx.doi.org/10.7150/ntno.49614] [PMID: 33391976]
[78]
Golkowski, M.; Lau, H.T.; Chan, M.; Kenerson, H.; Vidadala, V.N.; Shoemaker, A.; Maly, D.J.; Yeung, R.S.; Gujral, T.S.; Ong, S.E. Pharmacoproteomics identifies kinase pathways that drive the epithelial-mesenchymal transition and drug resistance in hepatocellular carcinoma. Cell Syst., 2020, 11(2), 196-207.e7.
[http://dx.doi.org/10.1016/j.cels.2020.07.006] [PMID: 32755597]
[79]
Wei, L.; Lee, D.; Law, C.T.; Zhang, M.S.; Shen, J.; Chin, D.W.; Zhang, A.; Tsang, F.H.; Wong, C.L.; Ng, I.O.; Wong, C.C.; Wong, C.M. Genome-wide CRISPR/Cas9 library screening identified PHGDH as a critical driver for Sorafenib resistance in HCC. Nat. Commun., 2019, 10(1), 4681.
[http://dx.doi.org/10.1038/s41467-019-12606-7] [PMID: 31615983]
[80]
Roudi, R.; D’Angelo, A.; Sirico, M.; Sobhani, N. Immunotherapeutic treatments in hepatocellular carcinoma; achievements, challenges and future prospects. Int. Immunopharmacol., 2021, 101(Pt A), 108322.
[http://dx.doi.org/10.1016/j.intimp.2021.108322] [PMID: 34735916]

Rights & Permissions Print Cite
Article Metrics
23
1
© 2024 Bentham Science Publishers | Privacy Policy